• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chronic kidney disease: epic battles in the phosphate-binder wars-the last episode?

作者信息

Covic Adrian, Voroneanu Luminita

机构信息

Nephrology Clinic, Dialysis and Renal Transplant Center, C. I. Parhon University Hospital, Romania.

出版信息

Nat Rev Nephrol. 2013 Sep;9(9):497-8. doi: 10.1038/nrneph.2013.149. Epub 2013 Jul 30.

DOI:10.1038/nrneph.2013.149
PMID:23897320
Abstract
摘要

相似文献

1
Chronic kidney disease: epic battles in the phosphate-binder wars-the last episode?慢性肾脏病：磷结合剂之战中的持久战——终章？
Nat Rev Nephrol. 2013 Sep;9(9):497-8. doi: 10.1038/nrneph.2013.149. Epub 2013 Jul 30.
2
[Phosphate binders in chronic kidney disease: the positions of sevelamer].慢性肾脏病中的磷结合剂：司维拉姆的地位
Ter Arkh. 2013;85(6):96-9.
3
Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.慢性肾脏病高磷血症患者中磷结合剂的疗效和安全性比较。
JPEN J Parenter Enteral Nutr. 2018 May;42(4):766-777. doi: 10.1177/0148607117715440. Epub 2017 Dec 19.
4
Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.司维拉姆与钙基结合剂治疗慢性肾脏病高磷血症的比较：随机对照试验的荟萃分析
Clin J Am Soc Nephrol. 2016 Feb 5;11(2):232-44. doi: 10.2215/CJN.06800615. Epub 2015 Dec 14.
5
Use of phosphate binders in chronic kidney disease.慢性肾脏病中磷酸盐结合剂的应用。
Curr Opin Nephrol Hypertens. 2013 Jul;22(4):413-20. doi: 10.1097/MNH.0b013e32836214d4.
6
Optimal use of phosphate binders in chronic kidney disease.慢性肾脏病中磷结合剂的最佳应用。
Expert Opin Pharmacother. 2013 Dec;14(18):2521-32. doi: 10.1517/14656566.2013.852183. Epub 2013 Nov 12.
7
A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?慢性肾脏病中磷结合剂的研究进展：是增量进步还是仅仅增加了成本？
Drugs. 2017 Jul;77(11):1155-1186. doi: 10.1007/s40265-017-0758-5.
8
Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?慢性肾脏病：磷结合剂治疗——坚固堡垒出现裂痕？
Nat Rev Nephrol. 2012 Nov;8(11):615-6. doi: 10.1038/nrneph.2012.219. Epub 2012 Oct 9.
9
The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.司维拉姆和镧与含钙及铁基结合剂治疗慢性肾脏病患者高磷血症的疗效和安全性：一项系统评价和荟萃分析。
Nephrol Dial Transplant. 2017 Jan 1;32(1):111-125. doi: 10.1093/ndt/gfw312.
10
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.慢性肾脏病中磷结合剂的益处与危害：随机对照试验的系统评价
Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18.

本文引用的文献

1
Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial.在新进入血液透析的患者中，司维拉姆与碳酸钙的比较：一项为期 24 个月、开放性、随机临床试验的结果。
Am J Kidney Dis. 2013 Oct;62(4):771-8. doi: 10.1053/j.ajkd.2013.03.023. Epub 2013 May 16.
2
Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.血清成纤维细胞生长因子 23 与矿物质代谢和心血管病理相关的心血管事件风险。
Clin J Am Soc Nephrol. 2013 May;8(5):781-6. doi: 10.2215/CJN.09570912. Epub 2013 Jan 18.
3
Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.
肾衰竭高磷血症的治疗药物：争议与展望。
Ther Adv Chronic Dis. 2012 Mar;3(2):59-68. doi: 10.1177/2040622311433771.
4
A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.在英国，对接受透析治疗的慢性肾脏病患者中与高磷血症相关的西那卡塞进行建模经济评估。
J Med Econ. 2013;16(1):1-9. doi: 10.3111/13696998.2012.718019. Epub 2012 Sep 10.
5
Mortality in kidney disease patients treated with phosphate binders: a randomized study.用磷酸盐结合剂治疗的肾病患者的死亡率：一项随机研究。
Clin J Am Soc Nephrol. 2012 Mar;7(3):487-93. doi: 10.2215/CJN.03820411. Epub 2012 Jan 12.
6
Prescribed dietary phosphate restriction and survival among hemodialysis patients.透析患者的规定饮食磷酸盐限制与生存。
Clin J Am Soc Nephrol. 2011 Mar;6(3):620-9. doi: 10.2215/CJN.04620510. Epub 2010 Dec 9.
7
Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease.慢性肾脏病中矿物质代谢紊乱与全因死亡率、心血管死亡率及心血管事件风险之间关联的证据的系统评价
Nephrol Dial Transplant. 2009 May;24(5):1506-23. doi: 10.1093/ndt/gfn613. Epub 2008 Nov 11.
8
A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data.司维拉姆与钙基磷酸盐结合剂对血液透析患者死亡率、住院率和发病率影响的比较：利用索赔数据对透析临床结局再评估（DCOR）随机试验的二次分析
Am J Kidney Dis. 2008 Mar;51(3):445-54. doi: 10.1053/j.ajkd.2007.12.002.
9
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community.社区中血清磷和钙水平与心血管疾病发病率的关系。
Arch Intern Med. 2007 May 14;167(9):879-85. doi: 10.1001/archinte.167.9.879.
10
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.冠状动脉钙化和磷结合剂选择对新发血液透析患者死亡率的影响
Kidney Int. 2007 Mar;71(5):438-41. doi: 10.1038/sj.ki.5002059. Epub 2007 Jan 3.